Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Earth is 70% ocean and 70% ocean bottom!
- How can we access the deep ocean systems?
- Deep ocean sediment sampling
- Unknown actinomycete bacteria cultivated
- New phylogenetic diversity: marine actinomycetes
- Bioactive marine microbial metabolites
- Problems with marine microbial drug discovery
- Three species of Salinispora recognized
- Chemical study - Salinispora tropica CNB-440
- Salinosporamide A, a potent anticancer agent
- Sal A proteasome enzymatic specificity
- Sal A reactivity during binding to 20S proteasome
- Ammosamides A and B - Mar 14 group
- Ammosamides A and B
- Ammosamides A and B cancer bioactivities
- Cell cycle response to ammosamide B
- Protein target of ammosamide B
- Protein target of ammosamide B is myosin II
- X-ray structure of myosin II
- Predicted myosin II binding site (docking studies)
- The MAR 4 actinomycetes - Streptomycetaceae
- The MAR 4 actinomycetes metabolites
- Napyradiomycins induce rapid cytotoxicity
- Napyradiomycins and apoptosis in HCT-116 cells
- Preparation of fluorescent coumarin derivatives
- Two MAR 4 probes bind to the ER in HeLa cells
- Immunoprecipitation leads to “Grp94” as target
- Role of the Hsp90 proteins in cell regulation
- Streptomyces strain CNH-287, a new species
- X-ray structure of chlorizidine A
- Reactivity of chlorizidine A
- Synthesis of the chlorizidine A fluorescent probe
- Incubation of chlorizidine A probe & HCT-116 cells
- Immunoprecipitation leads to ID of ENO1
- Crystal structure of human enolase 1
- Concluding remarks
- Acknowledgements
Topics Covered
- Structurally unprecedented marine bacterial metabolites
- Developing new molecules for the treatment of cancer
- Discovery of the protein targets of apoptosis-inducing metabolites
- Developing the potential of natural products to treat cancer by alternative mechanisms of action
- Discoveries of GRP94, myosin II and related cellular proteins as targets of new cytotoxins
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Fenical, W. (2021, September 23). Deep ocean microorganisms yield mechanistically-novel anticancer agents [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/OVMW7974.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. William Fenical has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Deep ocean microorganisms yield mechanistically-novel anticancer agents
A selection of talks on Microbiology
Hide